Trading status Status de
  • Prices realtime
    • Indizes
      • UC DAX
      • UC MDAX
      • UC TECDAX
      • UC DJI
      • UC ESTOXX
      • UC NASQAD 100
    • Shares
    • ETFs & FUNDS
    • Bonds
    • Crypto
  • Screen markets
    • Stock screener
    • Certifcate Screener
    • ETF Screener
    • Fund Screener
    • Bond screener
  • Trading ideas
    • risk indices
      • risk indices
      • EU Intraday
      • EU Long Term
      • US Intraday
      • US Longterm
    • New on gettex
      • New listings stocks
      • New listings bonds
      • New intraday certificates
    • Blog
    • Newsletter
    • Watchlist
    • Support
  • Trading
    • Trading Calendar
    • Extended trading hours
    • Listing on demand
    • Announcements
    • Quality Reports
    • Delayed Data
    • Regulations
    • Become a Trade Participant
    • Cancellations
  • About Gettex
    • FAQs
    • Press
    • Partners
    • Committees
    • Career
    • Career
    • Service & Contact
  • Why gettex

News overview

  • «
  • ‹
  • …
  • 7796
  • 7797
  • 7798
  • …
  • ›
  • »

2025-10-17

Bank First Corporation Receives Regulatory Approval to Acquire Centre 1 Bancorp, Inc.

2025-10-17

Colabor Group Reports Results for the Third Quarter 2025 and Provides a Corporate Update

2025-10-17

CHINA TOWER Extends Depreciation Period for DAS Assets to 10 Yrs, Expected to Reduce Annual Depreciation by RMB870M

2025-10-17

Lagardere Q3 Revenue Up 5.4%

2025-10-17

Why Adore Beauty, Iress, Jumbo, and Newmont shares are storming higher today

2025-10-17

Japan′s Ebara to raise chip plant pump output in China and South Korea

2025-10-17

Here€s How Much You Would Have Made Owning The Hartford Insurance Gr Stock In The Last 5 Years

2025-10-17

Here€s How Much You Would Have Made Owning Laureate Education Stock In The Last 5 Years

2025-10-17

IDACORP raises quarterly dividend by 2.3% to $0.88/share

2025-10-17

Canlan Ice Sports declares $0.50 dividend

2025-10-17

FVCBankcorp declares $0.06 dividend

2025-10-17

Junshi Biosciences Announces FDA′s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

  • «
  • ‹
  • …
  • 7796
  • 7797
  • 7798
  • …
  • ›
  • »

Preset online depot

Favorites: Zertifikate-Finder FAQs Newsletter
Realtimeprices 09/Apr/2026 12:54:23
Tradingtime Mo-Fr: 7:30-23 h
Certificates 8:00-22 h
  • Imprint
  • Legal notice
  • Data protection
  • Contact
  • Cookies